Omnia Family Wealth’s Akari Therapeutics AKTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
Sell
-711
Closed -$28.7K 103
2025
Q3
$28.7K Sell
711
-856
-55% -$33.3K 0.01% 101
2025
Q2
$73.3K Sell
1,567
-624
-28% -$31.5K 0.03% 101
2025
Q1
$109K Hold
2,191
0.05% 90
2024
Q4
$107K Hold
2,191
0.04% 78
2024
Q3
$259K Hold
2,191
0.11% 69
2024
Q2
$237K Hold
2,191
0.1% 71
2024
Q1
$163K Hold
2,191
0.08% 73
2023
Q4
$273K Buy
2,191
+713
+48% +$94.3K 0.14% 54
2023
Q3
$234K Buy
1,478
+500
+51% +$77.3K 0.14% 57
2023
Q2
$133K Hold
978
0.09% 65
2023
Q1
$142K Hold
978
0.11% 65
2022
Q4
$368K Hold
978
0.3% 43
2022
Q3
$493K Buy
978
+30
+3% +$24.7K 0.41% 28
2022
Q2
$758K Hold
948
0.56% 24
2022
Q1
$910K Buy
948
+114
+14% +$120K 0.6% 23
2021
Q4
$1M Buy
834
+250
+43% +$322K 0.61% 24
2021
Q3
$761K Hold
584
0.52% 29
2021
Q2
$808K Buy
584
+63
+12% +$101K 0.52% 27
2021
Q1
$1.1M Buy
521
+32
+7% +$72.5K 0.82% 21
2020
Q4
$724K Hold
489
0.66% 26
2020
Q3
$681K Hold
489
0.65% 28
2020
Q2
$854K Buy
489
+259
+113% +$395K 0.84% 19
2020
Q1
$267K Buy
230
+18
+8% +$25.1K 0.28% 56
2019
Q4
$297K Buy
+212
New +$313K 0.14% 73

Other funds holding AKTX

Omnia Family Wealth's AKTX Position: Q4 2025 in Review

Omnia Family Wealth sold out of Akari Therapeutics (AKTX) in Q4 2025, closing a stake of 711 shares — an estimated $28.7K sold.

Omnia Family Wealth first reported a position in AKTX in Q4 2019 and held it in 24 quarters. The position peaked at $1.1M in Q1 2021. 19 funds tracked by Wall St. Rank hold AKTX as of Q4 2025.

  • Omnia Family Wealth reported no remaining Akari Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Omnia Family Wealth sold 711 Akari Therapeutics shares in Q4 2025, an estimated $28.7K.
  • Omnia Family Wealth first reported a position in Akari Therapeutics in Q4 2019 and held it in 24 quarters.
  • Omnia Family Wealth's Akari Therapeutics position peaked at $1.1M in Q1 2021.
  • 19 funds tracked by Wall St. Rank held Akari Therapeutics as of Q4 2025.

Based on Omnia Family Wealth's 13F filing for Q4 2025, filed 16 Jan 2026.